For dementia, antipsychotic cost and coverage depend on your specific Part D formulary, tier, and utilization rules. Verify those three details before you assume a price or fill the prescription. Antipsychotics are medicines that act on brain chemicals linked to psychosis and severe agitation. Agitation tied to dementia due to Alzheimer's disease means restlessness, aggression, or distress that interferes with care.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What is approved for dementia-related agitation?
- Why does your plan decide the price?
- What plan rules can delay the fill?
- What should you verify before you pay?
What is approved for dementia-related agitation?
On May 11, 2023, the FDA granted supplemental approval to Rexulti, or brexpiprazole, for agitation tied to dementia due to Alzheimer's disease. According to the Alzheimer's Association, it was the first FDA-approved option for that indication, based on two 12-week trials, described in the FDA approval notice.
Approval matters because it shapes how a plan classifies the prescription. A prescription that matches the approved use moves through coverage review more directly. A use outside that wording faces closer review.
Why does your plan decide the price?
Medicare Part D treats antipsychotics as a protected class, so plans must include most of them. Each plan still sets its own formulary and tier, so coverage and copay vary by plan.
According to Medicare.gov, you must check your own plan formulary for placement and cost-sharing, explained in how Part D plans set formularies. The same drug can cost little in one plan and much more in another. Tier placement drives that difference.
What plan rules can delay the fill?
Even when a drug is listed, the plan may require prior authorization, step therapy, or quantity limits. Step therapy means trying a cheaper proven drug first when appropriate.
According to Medicare.gov, a prescriber can request an exception with medical-necessity justification, described in plan coverage rules and exceptions. Ask what reason the plan needs and who sends it. Get the request date, reference number, and response timeline in writing.
What should you verify before you pay?
Retail price without insurance and Part D price for the same drug can differ sharply. According to SingleCare data from 2024, average retail exceeds $2,050 for a 30-day supply without insurance, while average Medicare Part D cost is about $21 per month, reported in Rexulti costs with Medicare. Confirm these items with the plan and pharmacy before you commit:.
- formulary status, tier, and monthly copay for your dose
- prior authorization, step therapy, or quantity-limit requirements
- exception process, needed records, and expected decision date
- pharmacy choice and 30-day versus 90-day supply price
